Highly rated in
Highly rated in
Check Dr. Rami S. Owera's experience treating your condition:
About Dr. Rami S. Owera

Rami Owera is an Oncologist and a Hematologist Oncology expert in Pensacola, Florida. Owera has been practicing medicine for over 28 years and is highly rated in 53 conditions, according to our data. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer. He is licensed to treat patients in Florida and Alabama. Owera is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 17 clinical trials in the past 15 years.


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Rami S. Owera it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Rami S. Owera accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Bright Health
  •  Sunshine Health

Call to see if your plan is accepted.
2120 E Johnson Ave, Pensacola, FL 32514
Other Locations
4224 N Davis Hwy, Pensacola, FL 32503
6002 Berryhill Rd, Milton, FL 32570
4724 N Davis Hwy, Pensacola, FL 32503
Background & Education
Graduate Institution
Other, 1995
Hematology Oncology
Internal Medicine in AL
Hospital Affiliations
DW McMillan Memorial Hospital
Atmore Community Hospital
Ascension Sacred Heart Hospital Pensacola
Baptist Hospital
Gulf Breeze Hospital
HCA Florida West Hospital
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice
The Circulating Cell-free Genome Atlas Study
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
View 10 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors